Backgrounds and Aims: Previous studies have investigated that sarcopenia is associated with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis, and fibrosis in NAFLD. The study aims to investigate the risk for NAFLD, especially NAFLD-related significant fibrosis among subjects with sarcopenia. Methods: We searched electronic databases until 30, September 2017 and reviewed literature extensively. Effect estimates were pooled using random effect models regarding the risk for NAFLD and fixed effect models concerning the risk for significant fibrosis among sarcopenia patients. Sensitivity analysis was performed for the risk of NAFLD. Results: We identified 6 studies. Our results showed that subjects with sarcopenia exhibited an increased risk for NAFLD compared to those without sarcopenia (OR 1.29, 95% CI 1.12–1.49) with heterogeneity among the individual studies (I2 = 61%). And the risk for NAFLD-related significant fibrosis appeared to be more pronounced in sarcopenia patients (OR 1.57, 95% CI 1.29–1.90) with an I2 of 0%. Sensitivity analysis revealed that neither the direction nor the magnitude of the estimated pooled results for NAFLD was obviously affected. Furthermore, the pooled ORs were both close to initial analysis when omitting the study by Hong et al. [Hepatology 2014; 59: 1772–1778] (OR 1.24, 95% CI 1.11–1.39, I2 = 47%) or by Hashimoto et al. [Endocr J 2016; 63: 877–884] (OR 1.33, 95% CI 1.11–1.59, I2 = 67%), which were considered sources of heterogeneity. Conclusions: Our analysis demonstrated that sarcopenia served not only as a risk factor for the onset of NAFLD but also related to the progression of NAFLD-related significant fibrosis.

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ: The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592–1609.
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124–131.
Wijarnpreecha K, Panjawatanan P, Lekuthai N, Thongprayoon C, Cheungpasitporn W, Ungprasert P: Hyperuricaemia and risk of nonalcoholic fatty liver disease: a meta-analysis. Liver Int 2017; 37: 906–918.
Rinella ME: Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263–2273.
Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, Waljee AK: The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 2014; 109: 325–334.
Kim D, Kim WR, Kim HJ, Therneau TM: Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357–1365.
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, Hultcrantz R: Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547–1554.
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F: Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389–397.e310.
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K: Frailty in elderly people. Lancet 2013; 381: 752–762.
Dasarathy S, Merli M: Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol 2016; 65: 1232–1244.
Janssen I: The epidemiology of sarcopenia. Clin Geriatr Med 2011; 27: 355–363.
Walston JD: Sarcopenia in older adults. Curr Opin Rheumatol 2012; 24: 623–627.
The Lancet Diabetes Endocrinology: Sarcopenia: a fate worth challenging. Lancet Diabetes Endocrinol 2014; 2: 183.
Moon SS: Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009–2010. Endocr J 2014; 61: 61–70.
Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, de Rekeneire N, Harris TB, Kritchevsky S, Tylavsky FA, Nevitt M, Cho YW, Newman AB: Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 2009; 32: 1993–1997.
Atkins JL, Whincup PH, Morris RW, Lennon LT, Papacosta O, Wannamethee SG: Sarcopenic obesity and risk of cardiovascular disease and mortality: a population-based cohort study of older men. J Am Geriatr Soc 2014; 62: 253–260.
Rasmussen BB, Fujita S, Wolfe RR, Mittendorfer B, Roy M, Rowe VL, Volpi E: Insulin resistance of muscle protein metabolism in aging. FASEB J 2006; 20: 768–769.
Takamura T, Misu H, Ota T, Kaneko S: Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver. Endocr J 2012; 59: 745–763.
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catala-Lopez F, Gotzsche PC, Dickersin K, Boutron I, Altman DG, Moher D: The -PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777–784.
Herzog R, Alvarez-Pasquin MJ, Diaz C, Del Barrio JL, Estrada JM, Gil A: Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 2013; 13: 154.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
Hong HC, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM: Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 2014; 59: 1772–1778.
Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, Lee KL, Kim W: Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol 2017; 66: 123–131.
Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, Kang ES, Han KH, Lee HC, Cha BS: Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011). J Hepatol 2015; 63: 486–493.
Lee YH, Kim SU, Song K, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, Han KH: Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008–2011). Hepatology 2016; 63: 776–786.
Petta S, Ciminnisi S, Di Marco V, Cabibi D, Camma C, Licata A, Marchesini G, Craxi A: Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017; 45: 510–518.
Hashimoto Y, Osaka T, Fukuda T, Tanaka M, Yamazaki M, Fukui M: The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes. Endocr J 2016; 63: 877–884.
Treeprasertsuk S, Bjornsson E, Enders F, Suwanwalaikorn S, Lindor KD: NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 2013; 19: 1219–1229.
Lee SW, Youm Y, Lee WJ, Choi W, Chu SH, Park YR, Kim HC: Appendicular skeletal muscle mass and insulin resistance in an elderly Korean population: the Korean social life, health and aging project-health examination cohort. Diabetes Metab J 2015; 39: 37–45.
Skov-Jensen C, Skovbro M, Flint A, Helge JW, Dela F: Contraction-mediated glucose uptake is increased in men with impaired glucose tolerance. Appl Physiol Nutr Metab 2007; 32: 115–124.
Utzschneider KM, Kahn SE: Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753–4761.
Polyzos SA, Kountouras J, Zavos C: Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009; 9: 299–314.
Phielix E, Szendroedi J, Roden M: Mitochondrial function and insulin resistance during aging: a mini-review. Gerontology 2011; 57: 387–396.
Entingh-Pearsall A, Kahn CR: Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. J Biol Chem 2004; 279: 38016–38024.
Kalyani RR, Corriere M, Ferrucci L: Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol 2014; 2: 819–829.
Sumida Y, Yonei Y, Tanaka S, Mori K, Kanemasa K, Imai S, Taketani H, Hara T, Seko Y, Ishiba H, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Yasui K, Minami M, Itoh Y: Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease. Hepatol Res 2015; 45: 771–781.
Phillips T, Leeuwenburgh C: Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction. FASEB J 2005; 19: 668–670.
Tilg H, Moschen AR: Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836–1846.
Lawler JF, Jr., Yin M, Diehl AM, Roberts E, Chatterjee S: Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J Biol Chem 1998; 273: 5053–5059.
Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG: Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology 2006; 43: 474–484.
Rust C, Gores GJ: Apoptosis and liver disease. Am J Med 2000; 108: 567–574.
Seo JA, Cho H, Eun CR, Yoo HJ, Kim SG, Choi KM, Baik SH, Choi DS, Park MH, Han C, Kim NH: Association between visceral obesity and sarcopenia and vitamin D deficiency in older Koreans: the Ansan Geriatric Study. J Am Geriatr Soc 2012; 60: 700–706.
Liu G, Lu L, Sun Q, Ye X, Sun L, Liu X, Zong G, Jin Q, Li H, Lin X: Poor vitamin D status is prospectively associated with greater muscle mass loss in middle-aged and elderly Chinese individuals. J Acad Nutr Diet 2014; 114: 1544–1551.e1542.
Eliades M, Spyrou E: Vitamin D: a new player in non-alcoholic fatty liver disease? World J Gastroenterol 2015; 21: 1718–1727.
Bemben DA, Langdon DB: Relationship between estrogen use and musculoskeletal function in postmenopausal women. Maturitas 2002; 42: 119–127.
Moran AL, Warren GL, Lowe DA: Removal of ovarian hormones from mature mice detrimentally affects muscle contractile function and myosin structural distribution. J Appl Physiol 2006; 100: 548–559.
Sciote JJ, Horton MJ, Zyman Y, Pascoe G: -Differential effects of diminished oestrogen and androgen levels on development of skeletal muscle fibres in hypogonadal mice. Acta physiologica Scandinavica 2001; 172: 179–187.
Yuki A, Ando F, Otsuka R, Shimokata H: Low free testosterone is associated with loss of appendicular muscle mass in Japanese community-dwelling women. Geriatr Gerontol Int 2015; 15: 326–333.
Yuki A, Otsuka R, Kozakai R, Kitamura I, Okura T, Ando F, Shimokata H: Relationship between low free testosterone levels and loss of muscle mass. Sci Rep 2013; 3: 1818.
Senmaru T, Fukui M, Okada H, Mineoka Y, Yamazaki M, Tsujikawa M, Hasegawa G, Kitawaki J, Obayashi H, Nakamura N: Testosterone deficiency induces markedly decreased serum triglycerides, increased small dense LDL, and hepatic steatosis mediated by dysregulation of lipid assembly and secretion in mice fed a high-fat diet. Metabolism 2013; 62: 851–860.
Seo NK, Koo HS, Haam JH, Kim HY, Kim MJ, Park KC, Park KS, Kim YS: Prediction of prevalent but not incident non-alcoholic fatty liver disease by levels of serum testosterone. J Gastroenterol Hepatol 2015; 30: 1211–1216.
Kim M, Shinkai S, Murayama H, Mori S: Comparison of segmental multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiometry for the assessment of body composition in a community-dwelling older population. Geriatr Gerontol Int 2015; 15: 1013–1022.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.